Biomedical subjects

K Lühdorf

Publications and source records attributed to K Lühdorf.

4 recordsLinked to original sources

PubMed1978

Grand mal-provoked hyperuricemia.

A significant increase in S-urate was found postictally in 17 patients with two or more grand mal seizures within 24 h. In six patients S-urate was above the level at which hyperuricemic renal failure may develop. Impaired renal function was observed in two patients who had extremely high S-urates. It is proposed that prophylactic procedures against hyperuricemic renal failure should be carried out in all patients with repetitive convulsions.

Acute Kidney Injury↗

PubMed1977

Phenytoin-induced hyperkinesia.

Previously described cases of phenytoin-induced hyperkinesia are reviewed. Three new cases are reported, in one of which hyperkinesia persisted for 5 years, although serum phenytoin on several occasions was in the therapeutic range. Similarities between phenytoin-induced hyperkinesia and hyperkinesia in Huntington's chorea and in neuroleptic- and L-DOPA-treated patients are discussed. It is pointed out that the frequency of organic cerebral damage seems to be high among patients with phenytoin-induced hyperkinesia. The hypothesis is presented that phenytoin induces hyperkinesia by increasing dopaminergic and serotonergic activity in the basal ganglia, and that patients with preexisting basal ganglia damage are the most susceptible.

Adolescent↗

PubMed1977

Does alexia without agraphia always include hemianopsia?

A patient with alexia without agraphia (pure alexia) is reported. Bedside examination of the visual fields disclosed no abnormalities; but perimetric examination demonstrated an incomplete right homonymous hemianopsia with some sparing of the peripheral part of the visual field. The literature on pure alexia without hemianopsia is reviewed and it is concluded that this syndrome has hardly been described with certainity.

Dyslexia, Acquired↗

PubMed1975

The effect of L-dopa on young patients with simple schizophrenia, treated with neuroleptic drugs: a double-blind cross-over trial with Madopar and placebo.

Thirteen out of 18 young out-patients with simple schizophrenia under neuroleptic treatment completed a double-blind cross-over trial with Madopar [L-Dopa + benserazid (a peripheral decarboxylase inhibitor)] and placebo. Nine patients were given 900 mg L-Dopa + 225 mg benserazid daily, 1 patient received 600 mg L-Dopa + 150 mg benserazid, and 3 patients, 300 mg L-Dopa + 75 mg benserazid. In these doses, L-Dopa was effective against emotional withdrawal, blunted affect, tendency to isolation and apathy, without inducing or aggravating productive, accessory symptoms. The activity score, according to the specific activity-withdrawal scale, was significantly increased (P less than 0.05), whereas the total BPRS score (Brief Psychiatric Rating Scale) was slightly, but significantly reduced (P less than 0.05). In cases where L-Dopa had to be limited to 600 and 300 mg daily, a tendency to anxiety, distortion of thinking, and a sense of unreality were observed, depending on the dose of L-Dopa. In no case were gastrointestinal, cardiovascular or neurological side-effects observed.

Adult↗